Navigation Links
Research 2.0 Initiates Coverage of Viral Genetics and Publishes Research Report
Date:2/1/2011

SAN MARINO, Calif., Feb. 1, 2011 /PRNewswire/ -- Boston-based Research 2.0 initiated coverage of Viral Genetics, Inc, (Pink Sheets: VRAL) and published their initial report today. The report is available on the company's website at www.viralgenetics.com/investors/press-releases/R20Report and is also distributed over the internet and through institutional platforms including FactSet, CapitalIQ, and TheMarkets.com. Research 2.0 is pioneering a new "open professional" model of investment research which gives companies a direct path to quality independent institutional research coverage via an annual retainer and making that research broadly available to all potential investors on the Internet and in open social and professional online networks.

"We'll let the report and the Research 2.0 analysts speak for themselves, but suffice it to say that we're very happy to reach a new audience with a professional analysis and evaluation of the company at the same time that we've successfully transitioned from a preclinical to clinical stage biotech company," said Viral Genetics CEO Haig Keledjian.

Research 2.0's principals have over 50 years combined experience in traditional investment banking research and portfolio management, including the managing of a five hundred million dollar biotech investment management fund. The firm provides research coverage and advisory services to over two-dozen small, technology-focused public and private companies in a variety of sectors including life sciences, software, cloud computing and other technologies. Their research reports on clients are available through FactSet, CapitalIQ, and TheMarkets.com, as well as through subscription services. Additionally, over 12,000 individual investors, media, investment professionals and others subscribe to the Research 2.0 blog where founder and CEO, Kris Tuttle, writes additional updates and more informal notes about clients, the markets and other topics, available at http://blog.research2zero.com and syndicated to www.seekingalpha.com.

About Viral Genetics, Inc.

San Marino, California-based Viral Genetics discovers drug therapies. Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant tumors. A majority-owned subsidiary called VG Energy is dedicated to exploring biofuel and agricultural applications for one of the technologies in its licensed portfolio. Online at www.viralgenetics.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports. None of Viral Genetics' drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved. Contact:Haig Keledjian, Viral GeneticsT: (626) 334-5310
'/>"/>

SOURCE Viral Genetics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Department of Energy Funds SRI to Enhance Bioinformatics Tools for Renewable Energy Research
2. Practice Fusion Invites Health Researchers to Analyze This! Contest on Windows Azure
3. Cellectis bioresearch First to Launch Revolutionary Custom TAL Nuclease Service
4. Columbia University researchers use nanoscale transistors to study single-molecule interactions
5. Role of Market Research Evolving to Take on a More Strategic Responsibility
6. Leading Dental Stem Cell and Regenerative Medicine Researcher Dr. George Huang Joins StemSaves Science Advisory Council
7. Ingenuity Systems and Erasmus University Medical Center Collaborate on Next-Generation Sequencing Project to Accelerate Disease Research
8. New impulses for surface research
9. Nanomechanical Testing in Materials Research and Development
10. AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer
11. New research shows how light can control electrical properties of graphene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... 22, 2017 , ... Pharma and biotech consulting firm ... Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins brings 14 years ... than a decade with leading market research firm, GfK. He began his pharma ...
(Date:2/22/2017)... Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017 ... ) today announced its financial results for the ... "Our annual 2016 financial results reflect continued ... earnings exceeded $700 million," said Martine Rothblatt, Ph.D., ... financial results strengthen our ability to develop and ...
(Date:2/21/2017)... , Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... and operational results for the three months ended December 31, ... -based life sciences and diagnostics company that develops and ... ... continue to build on the commercial milestones achieved in fiscal ...
(Date:2/21/2017)... ... February 21, 2017 , ... Vortex Biosciences announced ... automated benchtop system for collecting intact circulating tumor cells (CTCs) that are shed ... Medicine Tri Conference (Tri-Con) Annual Meeting 2017 (February 19–24 San Francisco). , The ...
Breaking Biology Technology:
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
Breaking Biology News(10 mins):